BiotechTube
Home/Poseida Therapeutics/Bryan A. Kobel
BA

Bryan A. Kobel

Chief Financial Officer

Poseida Therapeutics

Therapeutic Areas

OncologyRare Diseases

Poseida Therapeutics Pipeline

DrugIndicationPhase
P-BCMA-ALLO1Relapsed/Refractory Multiple MyelomaPhase 1
P-MUC1C-ALLO1Solid Tumors (Breast, Ovarian, Pancreatic, etc.)Phase 1
P-PSMA-ALLO1Metastatic Castration-Resistant Prostate CancerPhase 1
P-BCMA-101Relapsed/Refractory Multiple MyelomaPhase 1/2
P-MOD-501Ornithine Transcarbamylase (OTC) DeficiencyPreclinical

Leadership Team at Poseida Therapeutics

EO
Eric Ostertag
Chief Executive Officer
KY
Kristin Yarema
President and Chief Operating Officer
SR
Syed Rizvi
Chief Medical Officer
BW
Brent Warner
President, Gene Therapy
MT
Matthew T. Spear
Chief Development Officer (former)
View full Poseida Therapeutics profile